A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (NCT04975308)
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.
Who can join: Review the eligibility criteria below.
Location: Ironwood Cancer & Research Centers — Chandler, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (243 Sites)
Showing the first 25 of 243 sites.
- Ironwood Cancer & Research Centers — Chandler, Arizona
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Marin Cancer Care — Greenbrae, California
- University of California Davis (UC Davis) Comprehensive Cancer Center — Sacramento, California
- Sharp Memorial Hospital — San Diego, California
- Banner MD Anderson Cancer Center at McKee Medical Center — Loveland, Colorado
- Clermont Oncology Center — Clermont, Florida
- University of Florida College of Medicine — Gainesville, Florida
- Mid Florida Hematology and Oncology Center — Orange City, Florida
- Florida Cancer Specialists — Sarasota, Florida
- Florida Cancer Specialists — St. Petersburg, Florida
- Kaiser Permanente Moanalua Medical Center — Honolulu, Hawaii
- University of Chicago Medical Center — Chicago, Illinois
- NorthShore University HealthSystem - Evanston Hospital — Evanston, Illinois
- IU Health Ball Memorial Hospital, Inc. — Muncie, Indiana
- The University of Louisville, James Graham Brown Cancer Center — Louisville, Kentucky
- Jackson Oncology Associates, PLLC — Jackson, Mississippi
- Care Access - Clifton — Clifton, New Jersey
- Memorial Sloan Kettering - Bergen — Montvale, New Jersey
- Columbia University Medical Center — New York, New York
- University of North Carolina Medical Center — Chapel Hill, North Carolina
- Aultman Hospital — Canton, Ohio
- Mercy Health - St. Vincent Medical Center — Toledo, Ohio
- Avera Cancer Institute Sioux Falls — Sioux Falls, South Dakota
- Florida Cancer Specialists — Nashville, Tennessee
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Neoplasms
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) — Birmingham, Alabama
- (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer — Phoenix, Arizona
- Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer — Dallas, Texas
- Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique — Fort-de-France,
- Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer — Springdale, Arkansas
- The IDEA Study (Individualized Decisions for Endocrine Therapy Alone) — Stanford, California
Explore by condition: All Breast Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.